ArticleHealth science reports2024

Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single-center cohorts study.

Akiko Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.